A Study of 1,236 Patients Supporting the Use of Unfractionated Heparin With or Without Glycoprotein IIb/IIIa Inhibitors over Bivalirudin in Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction: A Changing Trend-Juniper Publishers
JUNIPER PUBLISHERS-OPEN ACCESS JOURNAL OF CARDIOLOGY & CARDIOVASCULAR THERAPY Background The use of antithrombotic therapy such as heparin and bivalirudin are standard of practice in managing ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with a Class I recommendation. Recently the American College of Cardiology published in JACC: Cardiovascular Interventions a study analyzing the trends in anticoagulant use among 513,775 PCIs for STEMI from July 2009 through December 2014 utilizing information available from the National Cardiovascular Data Registry CathPCI Registry. In this study, bivalirudin was associated with a reduction in adverse bleeding events attributed to an increased use of glycoprotein IIb/IIIa inhibitors (GPI) alongside UFH. Objective: To report the efficacy and safety outcomes of UFH with routine use of GPI in primary PCI for STEMI in a high-risk population. Methods: Single center, re...